Vaxcyte, Inc. (PCVX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$64.14

From 52W high−13.74%

Volume2.55M

Market cap$10.02B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$64.14

From 52W high

−13.74%

Volume

2.55M

Market cap

$10.02B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.2x

P/E (TTM)

—

RSI (14)

53.6

MomentumView details →

1D Return

+0.09%

YTD Return

+41.65%

SummaryUpdated Jun 1, 2026

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company founded in 2013 and headquartered in San Carlos, California. Originally incorporated as SutroVax, Inc., the company rebranded to Vaxcyte in May 2020 and went public in June 2020. Vaxcyte specializes in developing novel protein vaccines designed to prevent or treat bacterial infectious diseases, with a particular focus on pneumococcal infections and other serious bacterial pathogens that pose significant public health challenges.

Ask drillr about Vaxcyte, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−38.59%

ROA (TTM)

−33.91%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−81.47%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−48.16%

EBITDA YoY

—

MomentumView details →

1D Return

+0.09%

YTD Return

+41.65%

1Y Return

+52.35%

RSI (14)

53.6

vs 50D SMA

+6.75%

vs 200D SMA

+16.03%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

5.72x

Quick Ratio

5.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.97

EPS Surprise

4.37%

Beats (12Q)

3/12

Next Q EPS Est

−$2.03

Avg Surprise (4Q)

−17.85%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−1.06B

Op. CF (TTM)

−1.16B

Next earningsNov 3, 2026 →

Latest newsMore news →

Vaxcyte, Inc. agreed to issue $575 million of 1.50% convertible senior notes due 2032, including a $75 million over-allotment option exercised in full.10d ago

Vaxcyte, Inc. commenced underwritten public offerings of $500 million of common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032.14d ago

Similar companies

Avidity Biosciences IncRNAM Jiangsu Zenergy Battery Technologies Group Co., Ltd.03677.HK Apogee Therapeutics, Inc.APGE GenFleet Therapeutics (Shanghai) Inc.02595.HK Nuvalent, Inc.NUVL Madrigal Pharmaceuticals, Inc.MDGL Find similar companies →

Latest newsMore news →

Vaxcyte, Inc. agreed to issue $575 million of 1.50% convertible senior notes due 2032, including a $75 million over-allotment option exercised in full.10d ago Vaxcyte, Inc. commenced underwritten public offerings of $500 million of common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032.14d ago Vaxcyte shares spiked 57% after its lead vaccine candidate showed trial results positioning it against Pfizer and Merck.14d ago